2026-10-14T22:10:05Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34046196 2026-10-01T14:08:36Z category_363 portal_316 item_type_3 month_year_10_2026

Table 1_Diagnostic spectrum and clinical outcomes of chronic inflammatory demyelinating polyneuropathy: a multicenter cohort.docx Reem M. Alhammad (20423909) Abdulrahman Ali (11735973) Roula Alhadyan (25156851) Ahmad R. Abuzinadah (25156854) Ahmed K. Bamaga (16845237) Muteb Alotaibi (25156857) Rawan Albalawi (25156860) Raseel Aljthalin (25156863) Raed Gasemaltayeb (25156866) Talal M. Al-Harbi (20423918) Faisal Tarabzouni (25156869) Hana Albulaihe (812436) Mohammed H. Alanazy (11405435) Meshal M. Alfallaj (25156872) Neurology and Neuromuscular Diseases chronic inflammatory demyelinating polyneuropathy EAN/PNS criteria immune-mediated polyneuropathy inflammatory polyneuropathy nerve conduction studies (NCS) Background<p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common immune-mediated demyelinating polyneuropathy, yet data from Arab populations are scarce. We present the first multicenter retrospective Arab cohort describing demographic, clinical, electrophysiological features, and treatment outcomes of CIDP.</p>Methods<p>Electronic records from five hospitals in Saudi Arabia were searched between January 2014 and January 2025 for patients diagnosed with CIDP. Patients meeting 2021 EAN/PNS criteria, aged 3 to 80 years, with a minimum follow-up of 3 months were included. Outcome at initial and last visit assessed using MRCSS and INCAT disability scores, with minimal clinically important differences defined as a 4-point and 1-point change in each score, respectively.</p>Results<p>Thirty-six (18 male, 18 female) met criteria (33 CIDP,3 possible CIDP). Onset age averaged 33 years (40 years in adult-onset cases). Typical CIDP was predominant (72%), with distal, motor-predominant, and multifocal variants representing 8% each. All motor demyelinating features were upper limb predominant. Maintenance monotherapy, mainly IVIG (42%) or oral steroids (33%), was used to treat 75% of patients. Over 55 months, meaningful improvement was achieved in 89% (INCAT) and 83% (MRCSS) with 3.7- and 11.9-point changes, respectively (p < 0.001). Relapses occurred in 42% at a mean of 11 months, mostly due to suboptimal response or non-compliance.</p>Conclusion<p>This is the first Arab multicenter CIDP study, which shows earlier disease onset than North American and European cohorts, with a similar clinical phenotype. Despite a 42% relapse rate, most patients showed meaningful improvement. These findings provide a regional benchmark for future prospective studies.</p> 2026-10-01T14:08:36Z Dataset Dataset 10.3389/fneur.2026.1958666.s001 https://figshare.com/articles/dataset/Table_1_Diagnostic_spectrum_and_clinical_outcomes_of_chronic_inflammatory_demyelinating_polyneuropathy_a_multicenter_cohort_docx/34046196 CC BY 4.0